-
FDA approves Admelog, the first follow-on insulin product to treat diabetes
europeanpharmaceuticalreview
December 13, 2017
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes…
-
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies
pharmafile
December 06, 2017
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and Tresiba, demonstrating the benefits they can provide to patients.
-
Microbial contamination forces Sun Pharma to recall two lots of diabetes drug in US
pharmaceutical-business-review
November 28, 2017
Sun Pharmaceutical Industries is voluntarily recalling two lots of diabetes drug Riomet in the US due to microbial contamination.
-
Health bodies test digital interventions for diabetes
pharmatimes
November 16, 2017
NHS England, Public Health England and Diabetes UK have teamed up with leading companies from the tech sector to test new digital approaches to fighting type II diabetes.
-
Psoriasis patients at greater risk of type 2 diabetes, study reveals
pharmafile
November 16, 2017
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk of developing type 2 diabetes, with more severe forms of the condition being linked to greater risk.
-
Harnessing immunotherapy to reverse Type 1 diabetes
fiercebiotech
November 16, 2017
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin
-
Eli Lilly announces an investment of US$72 million in core business
pharmaasia
November 01, 2017
The company has a nine decade legacy of researching and producing the drug.
-
New injectable Bydureon BCise for type-2 diabetes patients approved by FDA
pharmaasia
October 31, 2017
New Bydureon formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss.
-
Smart artificial beta cells could lead to new diabetes treatment
europeanpharmaceuticalreview
October 31, 2017
Researchers have designed synthetic beta cells that secrete insulin in response to high blood sugar…
-
US FDA approves Bydureon BCise by AstraZeneca for type-2 diabetes
biospectrumasia
October 24, 2017
It is an improved device provides significant HbA1c reduction with added benefit of weight loss
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
